Landos Biopharma, Inc. (LABP)

NASDAQ: LABP · IEX Real-Time Price · USD
3.64 0.25 (7.37%)
Jan 25, 2022 3:59 PM EST - Market closed
Market Cap152.62M
Revenue (ttm)n/a
Net Income (ttm)-29.67M
Shares Out41.93M
EPS (ttm)-0.97
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume69,877
Open3.30
Previous Close3.39
Day's Range3.03 - 3.64
52-Week Range2.78 - 16.99
Betan/a
AnalystsBuy
Price Target26.08 (+616.5%)
Earnings Daten/a

About LABP

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory ...

IndustryBiotechnology
IPO DateFeb 4, 2021
Employees33
Stock ExchangeNASDAQ
Ticker SymbolLABP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for LABP stock is "Buy." The 12-month stock price forecast is 26.08, which is an increase of 616.48% from the latest price.

Price Target
$26.08
(616.48% upside)
Analyst Consensus: Buy

News

Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization

2 months ago - GlobeNewsWire

Should You Buy Landos Biopharma (LABP) Ahead of Earnings?

Landos Biopharma (LABP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 months ago - Zacks Investment Research

Landos Biopharma Announces Leadership Transition

Josep Bassaganya-Riera Steps Down as Chairman, President and CEO

2 months ago - GlobeNewsWire

Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid Arthritis

Phase 1 trial is underway with topline results expected in the first half of 2022

2 months ago - GlobeNewsWire

Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus

Phase 1 trial initiation expected before yearend with topline results in 1H 2022

3 months ago - GlobeNewsWire

Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancor's ...

BLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and deve...

3 months ago - GlobeNewsWire

Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohn's Disease with the Icahn School of Medicine ...

Second Phase 2 trial of omilancor in Crohn's disease (CD), expected to initiate in 2021

4 months ago - GlobeNewsWire

Landos Biopharma to Participate in Two Upcoming Investor Conferences in September

BLACKSBURG, Va., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel or...

4 months ago - GlobeNewsWire

Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins Uni...

BLACKSBURG, Va., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel ora...

4 months ago - GlobeNewsWire

Landos Biopharma to Participate in Upcoming Investor Events

BLACKSBURG, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel ora...

5 months ago - GlobeNewsWire

Landos Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Updates

Following the recent positive End-of-Phase 2 meeting with the FDA, Landos initiated global pivotal  Phase 3 clinical trial site feasibility studies of omilancor in ulcerative colitis (UC)

5 months ago - GlobeNewsWire

Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference

BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and devel...

7 months ago - GlobeNewsWire

Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate ...

The FDA clears the path to initiate the PACIFY I and II global registration studies in Mild-to-Moderate Active UC patients representing the potential for a broad product label for Omilancor The FDA clea...

7 months ago - GlobeNewsWire

Landos Biopharma to Present at the Jefferies Virtual Healthcare Conference

BLACKSBURG, Va., May 25, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE A.I. platform to discover and develop novel o...

8 months ago - GlobeNewsWire

Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors

BLACKSBURG, Va., May 19, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients w...

8 months ago - GlobeNewsWire

Landos Biopharma, LianBio Ink Licensing Pact For Omilancor & NX-13 in Greater China

Landos Biopharma Inc (NASDAQ: LABP) and LianBio have announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China (mainlan...

8 months ago - Benzinga

Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates

Completed initial public offering of common stock, raising approximately $100 million in gross proceeds

8 months ago - GlobeNewsWire

Landos Biopharma to Present Two Late-Breaking Presentations on Therapeutic Potential of Omilancor and PX-69 at the 20...

BLACKSBURG, Va., April 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with...

8 months ago - GlobeNewsWire

Landos Biopharma Announces the Appointment of Tiago Girão to its Board of Directors

BLACKSBURG, Va., April 13, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with...

9 months ago - GlobeNewsWire

Landos Biopharma Stock Is Trading Higher On Initiating Early-Stage Study With Omilancor For Esophagus Inflammation

The FDA has signed off Landos Biopharma's (NASDAQ: LABP) Investigational New Drug application for omilancor (BT-11) for the treatment of Eosinophilic Esophagitis (EoE). Landos expects to initiate patien...

9 months ago - Benzinga

Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis

Third potential indication for omilancor (BT-11), a first-in-class candidate for the treatment of autoimmune diseases Third potential indication for omilancor (BT-11), a first-in-class candidate for the...

9 months ago - GlobeNewsWire

Landos Biopharma Announces Positive Results from a Phase 1 Study of NX-13 in Healthy Volunteers

NX-13 was well tolerated with no reported serious adverse events

10 months ago - GlobeNewsWire

Landos Biopharma to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

BLACKSBURG, Va., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (Nasdaq: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with ...

11 months ago - GlobeNewsWire

Landos Biopharma Announces Pricing of Initial Public Offering

BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune dise...

11 months ago - GlobeNewsWire